ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the resistance to TKIs conferred by ABCB1 expression was not as striking as for doxorubicin, adapting imatinib dose according to ABCB1 genotype might be interesting for CML patients.